NPPA, natriuretic peptide A, 4878

N. diseases: 217; N. variants: 11
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE Atrial and brain natriuretic peptides (ANP and BNP) are established diagnostic and prognostic markers in heart failure, but their utility in patients with advanced cancer is unclear. 31128228 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Biomarker disease BEFREE Atrial and brain natriuretic peptides (ANP and BNP) are established diagnostic and prognostic markers in heart failure, but their utility in patients with advanced cancer is unclear. 31128228 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE The findings suggested that a common NPPA SNPs rs5063 was associated with serum ANP levels and ANP was prospectively associated with hypertension in the Chinese Han population. 31341238 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE The natriuretic peptide (NP) family (including ANP (atrial natriuretic peptide), BNP (brain natriuretic peptide), and CNP (C-type natriuretic peptide)), the NP receptors (NPRA, NPRB, and NPRC), and the related protease convertases (furin, corin, and PCSK6) constitute the NP system and represent relevant protective mechanisms toward the development of hypertension and associated conditions, such as atherosclerosis, stroke, myocardial infarction, heart failure, and renal injury. 30781751 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE In contrast, levels of neprilysin (p<0.01), cGMP (p<0.001), and ANP (p<0.001) were higher in systolic dysfunction patients than controls and were the highest in patients with dHF. 30148170 2018
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE Functionally, knockdown of BRD4 greatly downregulated the NPPA and NPPB in vivo and in vitro, improved the hemodynamic and biometric parameters in rat with heart failure, as well as decreased the apoptosis occurrence. 29352508 2018
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Biomarker disease BEFREE Functionally, knockdown of BRD4 greatly downregulated the NPPA and NPPB in vivo and in vitro, improved the hemodynamic and biometric parameters in rat with heart failure, as well as decreased the apoptosis occurrence. 29352508 2018
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Biomarker disease BEFREE In contrast, levels of neprilysin (p<0.01), cGMP (p<0.001), and ANP (p<0.001) were higher in systolic dysfunction patients than controls and were the highest in patients with dHF. 30148170 2018
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 AlteredExpression disease BEFREE In mice with PPCM due to a cardiomyocyte-specific knockout of STAT3 (CKO) neither low nor high dose of recombinant Relaxin-2 (serelaxin, sRlx-LD: 30 µg/kg/day; sRlx-HD: 300 µg/kg/day) affected cardiac fibrosis, inflammation and heart failure but sRlx-HD increased capillary/cardiomyocyte ratio. sRlx-HD significantly increased heart/body weight ratio and cardiomyocyte cross-sectional area in postpartum CKO and wild-type mice without changing the foetal gene expression program (ANP or β-MHC). sRlx-HD augmented plasma Prolactin levels in both genotypes, which induced cardiac activation of STAT5. 28453725 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 AlteredExpression disease BEFREE In mice with PPCM due to a cardiomyocyte-specific knockout of STAT3 (CKO) neither low nor high dose of recombinant Relaxin-2 (serelaxin, sRlx-LD: 30 µg/kg/day; sRlx-HD: 300 µg/kg/day) affected cardiac fibrosis, inflammation and heart failure but sRlx-HD increased capillary/cardiomyocyte ratio. sRlx-HD significantly increased heart/body weight ratio and cardiomyocyte cross-sectional area in postpartum CKO and wild-type mice without changing the foetal gene expression program (ANP or β-MHC). sRlx-HD augmented plasma Prolactin levels in both genotypes, which induced cardiac activation of STAT5. 28453725 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE This study examined the SNPs AGT rs699 (Met235Thr), ADD1 rs4961 (rs4961" genes_norm="118">Gly460Trp), NPPA rs5063 (Val32Met), GPX1 rs1050450 (Pro198Leu), and AGTR1 rs5186 (A1166C) in relation to hypertension and salt sensitivity. 27480094 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE In whites, the minor G allele of the atrial natriuretic peptide (ANP) genetic variant rs5068 is associated with higher circulating levels of ANP and B-type natriuretic peptide (BNP), lower risk of hypertension, higher high-density lipoprotein (HDL) cholesterol plasma levels, and lower prevalence of obesity and metabolic syndrome. 29253899 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE As a risk factor, ANP gene polymorphisms may affect hypertension. 27413750 2016
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE Variants in the human NPPA gene, encoding the ANP precursor, are associated with hypertension, stroke, coronary artery disease, heart failure (HF) and obesity. 26074089 2015
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE The atrium is the major site of ANP synthesis, which has been said to increase in heart failure as a result of increased production in the left ventricular (LV) myocardium. 24599027 2014
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 GeneticVariation disease BEFREE Up-regulation was evident for muscle LIM protein (Mlp), desmin, and heart failure (natriuretic peptide A [Nppa], Nppb, and myosin heavy chain 6) and fibrosis (transforming growth factor beta 1, alpha-smooth muscle actin, osteopontin, and periostin) markers. 25541130 2014
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Biomarker disease BEFREE The atrium is the major site of ANP synthesis, which has been said to increase in heart failure as a result of increased production in the left ventricular (LV) myocardium. 24599027 2014
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 GeneticVariation disease BEFREE Up-regulation was evident for muscle LIM protein (Mlp), desmin, and heart failure (natriuretic peptide A [Nppa], Nppb, and myosin heavy chain 6) and fibrosis (transforming growth factor beta 1, alpha-smooth muscle actin, osteopontin, and periostin) markers. 25541130 2014
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE Among others, the 2238T>C exon 3 variant has been associated with endothelial cell damage and dysfunction and with an increased risk of acute cardiovascular events, a frameshift mutation within exon 3 has been related to increased risk of atrial fibrillation, and ANP gene variants have been linked to increased risk of hypertension in different ethnic groups. 24611929 2014
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Therapeutic disease RGD Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. 23931972 2013
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE In experimental early stage HF characterized with marked atrial fibrosis, ANP, BNP, and CNP mRNA, and protein concentrations were higher in HF LA but not HF LV compared with normals. 23152112 2013
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Therapeutic disease RGD Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. 23931972 2013
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Biomarker disease BEFREE In experimental early stage HF characterized with marked atrial fibrosis, ANP, BNP, and CNP mRNA, and protein concentrations were higher in HF LA but not HF LV compared with normals. 23152112 2013
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group CTD_human Quercetin inhibits left ventricular hypertrophy in spontaneously hypertensive rats and inhibits angiotensin II-induced H9C2 cells hypertrophy by enhancing PPAR-γ expression and suppressing AP-1 activity. 24039778 2013
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Therapeutic group CTD_human Quercetin inhibits left ventricular hypertrophy in spontaneously hypertensive rats and inhibits angiotensin II-induced H9C2 cells hypertrophy by enhancing PPAR-γ expression and suppressing AP-1 activity. 24039778 2013